 Home > Active Ingredient News > Antitumor Therapy > Ther Adv Med Oncol: Real-World Data Study of Treatment and Prognosis in Young (≤40 Years) Patients with Newly Diagnosed Metastatic Female Breast Cancer

Ther Adv Med Oncol: Real-World Data Study of Treatment and Prognosis in Young (≤40 Years) Patients with Newly Diagnosed Metastatic Female Breast Cancer

 Last Update: 2022-02-20
 Source: Internet
 Author: User

Tags

breast milk formed

rotella 15 40

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a French study was published in the journal Therapeutic Advances in Medical Oncology to explore the management and prognosis of young (≥40 years old) women with newly diagnosed metastatic breast cancer in the real world .

The study evaluated data on 22,463 40-year-old women with newly diagnosed MBC treated between 2008 and 2016 (NCT0327531)

4524 patients met the inclusion criteria, of whom 598 (13%) were ≤40 years old

Among HR+/HER2– patients, the majority (89.

first-line treatment

With a median follow-up of 49.

OS and PFS

In univariate analysis, younger age, HR+/HER2 and HER2+ subtype, low grade (I/II vs .

The median PFS1 was 14.

PFS

In the entire population, 96 patients had BRCA1/2 mutations, 44 of whom were ≤40 years of age
.
Grade III tumors were more common in younger BRCA patients (63.
4%, vs 49% in the overall population)
.
Most patients had HR+/HER2- and TNBC tumors (52.
3% and 43.
2%, respectively), and only 2 (4.
5%) patients had HER2+ tumors
.
Compared with older BRCA patients, younger BRCA women had fewer HR+/HER2- tumors (52.
3% vs 71.
2%) and more TNBC tumors (43.
2% vs 17.
3%)
.
Older women with BRCA had more bone metastases than younger women (73.
1% vs 43.
2%, p = 0.
0030)
.
The vast majority of young and older women with BRCA received CT as first-line therapy (97.
7% vs 86.
5%, p = 0.
07)
.

In conclusion, the study showed that among patients with newly diagnosed metastatic breast cancer, the median OS of younger patients (≤40 years old) was better than that of patients aged 41-69 years
.
The prognosis of patients with different subtypes varies greatly, which deserves further study
.
Studies have shown that among patients with newly diagnosed metastatic breast cancer, younger patients (≤40 years) have a better median OS than patients aged 41-69 years
.
The prognosis of patients with different subtypes varies greatly, which deserves further study
.
Studies have shown that among patients with newly diagnosed metastatic breast cancer, younger patients (≤40 years) have a better median OS than patients aged 41-69 years
.
The prognosis of patients with different subtypes varies greatly, which deserves further study
.

Original source:

Amélie Mallet, Amélie Lusque, Christelle Levy, et al.
Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer.
Ther Adv Med Oncol.
2022, Vol.
14: 1-15 .
DOI: 10.
1177/17588359211070362.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.